References
- Cramer P, and Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020;25(1):49–58.
- Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48(6):751–755.
- de Oliveira ECV, Da Motta VRV, Pantoja PC, et al. Actinic keratosis – review for clinical practice. Int J Dermatol. 2019;58(4):400–407.
- Rajaratnam R. Resiquimod for actinic keratosis: is this a new treatment option? Br J Dermatol. 2019;180(2):254–255.
- Stockfleth E, Hofbauer GFL, and Reinhold U, et al. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol. 2019;180(2):297–305.
- Szeimies R-M, Bichel J, Ortonne J-P, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205–210.